Travere Therapeutics (TVTX) Cash from Discontinued Operations (2022 - 2024)

Travere Therapeutics (TVTX) has 3 years of Cash from Discontinued Operations data on file, last reported at 7089000.0 in Q4 2024.

• Quarterly Cash from Discontinued Operations fell 16.21% year-over-year to 7089000.0 in Q4 2024, while the trailing twelve-month figure through Sep 2025 was 7089000.0 (down 9.7% YoY) and the FY2024 annual result came in at 7451000.0, down 116.44% from the prior year.
• Cash from Discontinued Operations fell to 7089000.0 in Q4 2024, from 50000.0 in the prior quarter.
• In the past five years, Cash from Discontinued Operations ranged from a high of 22064000.0 in Q4 2022 to a low of 7089000.0 in Q4 2024.
• A 3-year average of 6661000.0 and a median of 50000.0 in 2024 frame the typical range for Cash from Discontinued Operations.
• Annual changes were most pronounced in 2023 — Cash from Discontinued Operations slumped 127.65% — and 2024, when it retreated 16.21%.
• Tracing TVTX's Cash from Discontinued Operations over 3 years: stood at 22064000.0 in 2022, then tumbled by 127.65% to 6100000.0 in 2023, then declined by 16.21% to 7089000.0 in 2024.
• The last three Cash from Discontinued Operations figures came in at 7089000.0 (Q4 2024), 50000.0 (Q3 2024), and 309000.0 (Q2 2024), per Business Quant data.